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Abstract
Background: It is unknown whether HIV-positive patients experiencing virologic failure (VF) on boosted-PI (PI/r) regimens
without drug resistant mutations (DRM) by standard genotyping harbor low-level PI resistant variants. CASTLE compared
the efficacy of atazanavir/ritonavir (ATV/r) with lopinavir/ritonavir (LPV/r), each in combination with TVD in ARV-naı ¨ve
subjects.
Objective: To determine if VF on an initial PI/r-based regimen possess low-level resistant variants that may affect a
subsequent PI-containing regimen.
Methods/Results: Patients experiencing VF on a Tenofovir/Emtricitabine+PI/r regimen were evaluated by ultra deep
sequencing (UDS) for mutations classified/weighted by Stanford HIVdb. Samples were evaluated for variants to 0.4% levels.
36 VF subjects were evaluated by UDS; 24 had UDS for PI and RT DRMs. Of these 24, 19 (79.2%) had any DRM by UDS. The
most common UDS-detected DRM were NRTI in 18 subjects: M184V/I (11), TAMs(7) & K65R(4); PI DRMs were detected in 9
subjects: M46I/V(5), F53L(2), I50V(1), D30N(1), and N88S(1). The remaining 12 subjects, all with VLs,10,000, had protease
gene UDS, and 4 had low-level PI DRMs: F53L(2), L76V(1), I54S(1), G73S(1). Overall, 3/36(8.3%) subjects had DRMs identified
with Stanford-HIVdb weights .12 for ATV or LPV: N88S (at 0.43% level-mutational load 1,828) in 1 subject on ATV; I50V
(0.44%-mutational load 110) and L76V (0.52%-mutational load 20) in 1 subject each, both on LPV. All VF samples remained
phenotypically susceptible to the treatment PI/r.
Conclusion: Among persons experiencing VF without PI DRMs with standard genotyping on an initial PI/r regimen, low-
level variants possessing major PI DRMs were present in a minority of cases, occurred in isolation, and did not result in
phenotypic resistance. NRTI DRMs were detected in a high proportion of subjects. These data suggest that PIs may remain
effective in subjects experiencing VF on a PI/r-based regimen when PI DRMs are not detected by standard or UDS
genotyping.
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Introduction
HIV treatment guidelines recommend combination antiretro-
viral (ARV) regimens for treatment naive patients consisting of a
nucleoside/nucleotide reverse transcriptase inhibitor (N(t)RTI)-
based backbone along with either a non-nucleoside reverse
transcriptase inhibitor (NNRTI), an integrase inhibitor (INI) or a
ritonavir (RTV)-boosted protease inhibitor (PI) [1]. At the end of
2009, 584,000 HIV positive patients under care were receiving
ARVs in the USA [2]. Approximately 40% of patients were
initiated on an N(t)RTI+RTV-boosted PI (PI/r) as a first line
regimen [2].
The most common drug resistance mutation pattern by
standard HIV genotyping in patients experiencing virologic failure
on an initial regimen of Tenofovir/Emtricitabine (TDF/FTC) plus
a ritonavir boosted protease inhibitor (PI/r) is a solitary reverse
transcriptase (RT) M184V mutation or no resistance mutations
[3–7]. It is not known if HIV patients on a PI/r regimen
experiencing virologic failure without evidence of PI resistance
mutations by standard genotyping harbor low-level PI-resistant
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methods. Further, if low-level resistant variants exist in these
patients, could they affect the use of a subsequent PI/r containing
regimen?
The objective of this study was to determine if patients with
virologic failure on an initial PI/r-based regimen without
resistance by standard genotyping possess low-level drug resistant
variants that could affect the use of a subsequent PI/r containing
regimen. To investigate this question, ultra deep sequencing was
performed on the virologic failure specimens from the CASTLE
study [5–7]. CASTLE compared the efficacy of atazanavir/
ritonavir (ATV/r) with lopinavir/ritonavir (LPV/r), each in
combination with TDF/FTC in ARV-naı ¨ve patients through 96
weeks of treatment [5–7].
Methods
All available Week 48 and 96 CASTLE virologic failure
specimens from patients without PI resistance mutations by
standard genotype were evaluated by ultra deep sequencing
(454-Life Sciences/Roche, Branford, CT) for N(t)RTI+PI/r
mutations (see Figure 1a) and classified by Stanford HIVdb
algorithm [8]. Virologic failure specimens with HIV viral loads
.1,000 copies/mL allowed for ultra deep sequencing to be
attempted. Ultra deep sequencing was performed on both the
protease (PR) and RT genes for virologic failure specimens with
HIV viral load .10,000 c/mL. Virologic failure specimens with
HIV viral loads ,10,000 c/mL had ultra deep sequencing
performed only for the PR gene. All drug resistance mutations
and polymorphisms were evaluated by Stanford HIV db
algorithm; specific PI mutations with a value .12 for the PI used
in the study (ATV and LPV) were considered significant resistance
mutations. Ultra deep sequencing was performed as described in
previous studies [9–10]. Ultra deep sequencing was performed to
0.4% variant detection levels depending upon the sample HIV
viral load. Sampling of HIV RNA from a plasma sample follows
Poisson distribution and is subject to the stochastic effects of
sampling variation [9,11,12]. An estimated mutational load (ML)
was calculated by percent of variant detected x sample viral load
(Roche Amplicor Assay). Historical standard genotypes and
phenotypes were available on all CASTLE specimens for baseline
and virologic failure samples (Monogram Biosciences, South San
Francisco, CA). Susceptibility cut-off used for TDF, FTC, ATV/
RTV and LPV/RTV in CASTLE were clinical cut-offs (fold
change-FC) from Monogram Biosciences (TDF.1.4, FTC/
3TC.3.5, ATV/RTV.5.2, LPV/RTV.9).
All IRB approvals for this study were already obtained under
the parent CASTLE study. All subjects had given informed
consent. The parent CASTLE study is registered with Clinical-
Trials.gov, number NCT00272779.
Results
Of 78 patients with virologic failure at Weeks 48 and/or 96
from the CASTLE study without PI resistance mutations by
standard genotype, 57 were available for ultra deep sequencing
(Figure 1a). Of the 57 virologic failure specimens, 36 had a viral
load .1,000 copies/mL, which allowed for ultra deep sequencing
to be attempted. Ultra deep sequencing was performed on both
the PR and RT genes for all 24 (66.7%) specimens with HIV viral
load .10,000 c/mL. The remaining 12 (33.3%) virologic failure
specimens with HIV viral loads ,10,000 c/mL had ultra deep
sequencing performed only for the PR gene (Figure 1a). For the 24
samples with ultra deep sequencing for both PR and RT, 5/24
(20.8%) were wild type at all codon positions (no resistance
mutations). Nineteen of 24 (79.2%) had any PI, N(t)RTI and/or
NNRTI resistance mutations; 18/24 (75%) had N(t)RTI muta-
tions: M184V/I (11), TAMs(7) and K65R (4), and 9/24 (37.5%)
had PI mutations: M46I/V(5), F53L(2), I50V(1), D30N(1) &
N88S(1) (Figure 1b). Of the 12 specimens that had ultra deep
sequencing of only the protease gene, 4/12 (33.3%) had low level
PI mutations: F53L(2), L76V(1), I54S(1) and G73S(1) (Figure 1b).
Overall, 3/36 (8.3%) patients had PI mutations identified with
Stanford-HIVdb weights .12 for ATV or LPV: 1 patient on ATV
with N88S (0.43%-mutation load 1,828) and 2 patients on LPV:
one with I50V (0.44%-mutation load 110) and the remaining
patient with L76V (0.52%-mutation load 20). The mutations
identified by UDS in each specimen and the estimated mutational
loads with the corresponding phenotypes are listed in Table S1
and Table S2. All samples with low-level variants with PI
mutations remained phenotypically susceptible to PIs (Table S1
and Table S2-Historical phenotypes). Out of 11 patients with
M184V/I at virologic failure, 4 with M184V developed
phenotypic resistance to FTC/3TC (variant range 95.93% to
100%; phenotypic range 57.54 to 75.63). Of the seven patients
with a M184V/I without phenotypic resistance to 3TC/FTC, the
variant levels ranged from 0.42% to 31.1%. Four patients had a
K65R at virologic failure (variant range 0.52% to 1.28%), and
none developed phenotypic resistance to TDF (Table S1).
Discussion
The results from this study demonstrated that among patients
on an initial PI/r based regimen experiencing virologic failure
without PI resistance mutations by standard genotyping, low-level
variants possessing major PI mutations were present in a minority
of cases, occurred in isolation, and did not result in phenotypic PI
resistance. Only 3 patients (8.3%) had a PI mutation with a
Stanford algorithm weight .12 for the PIs used in the study (ATV
or LPV). However, they were at very low levels with low
mutational loads. It should be noted that none of the low-level
variants with a major PI mutation were at levels $1% of the viral
population, a level that has been shown to be clinically significant
for NNRTIs based regimens [9]. However, the PI mutations
identified in these specimens were known to be associated with
drug resistance to the corresponding PI. Of note, N(t)RTI
resistance mutations were detected in a high proportion (75%) of
virologic failure specimens and with greater frequency than PI
mutations, which may partly explain the viral breakthrough in
these patients. Interestingly, not all patients with M184V/I
developed phenotypic resistance to FTC/3TC. Eleven of 24
patients had low or high level M184V/I variants; 7 had M184V/I
at $1% of the viral population, however only 4 of the 7 developed
phenotypic resistance to FTC/3TC (all had M184V variant levels
.95%). None of the patients with K65R (all at ,2%) developed
phenotypic resistance to TDF (See Table S1).
These findings underscore the limitation of stand-alone
phenotypic susceptibility results and emphasize the importance
of complementary and/or more sensitive genotyping techniques
when evaluating for resistance [13]. In addition, these data further
suggest that the impact of drug resistance mutations on therapy is
multi-factorial and should take into account the proportion of the
variant present, the mutational load, and the specific mutation
present [10].
As previously reported by our group, low-level variants
possessing PI mutations are infrequently identified in treatment-
naı ¨ve persons and did not significantly affect the efficacy of PI/r
based regimens [14], a finding in contrast to low-level NNRTI
resistance mutations and NNRTI-based regimens [9]. In this
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also infrequently detected by ultra deep sequencing when patients
experience virologic failure on TDF/FTC+PI/r without PI
mutations detected by standard genotype.
The results of this study may have implications for first line and
subsequent ARV sequencing strategies. According to current
guidelines, second line ARV regimens for subjects with resistance
to NNRTI or PI/r based regimen should consist of at least 2,
preferably 3 new and fully susceptible ARVs [1]. This decision
should be based on drug history, genotypic and phenotypic data,
and the mechanism of action of the new drugs. Of note, drug
potency and viral susceptibility are as important as the number of
new drugs prescribed [1]. As shown in this study, patients who
failed a PI/r regimen in CASTLE without PI resistance by
standard genotype while remaining phenotypically susceptible
infrequently had low level variants resistant to the PI/r used or to
any other relevant PI/r. This data suggest that boosted PIs may
still provide good safety and efficacy and could possibly be re-used
in later lines of therapy with a different ARV backbone if no PI
mutations are present by ultra deep sequencing and as long as
adherence is addressed. However, this hypothesis would need to
be formally tested in clinical studies.
Our study had several limitations. Given the requirement for
other predetermined study analyses we were only able to recover
Figure 1. Description and UDS results for virologic failure samples. a: Virologic failure samples for UDS. UDS: Ultra Deep Sequencing; VF:
Virologic Failure. 78 subjects had virologic failure at week 48 and/or 96. *21 samples were either exhausted or could not be located. 57 patients with
virologic failure without PI resistance had samples for UDS. 21 patients failed with HIV RNA,1,000 copies and UDS could not be performed. 36
unique patients had UDS data. b: UDS results for 36 Virologic Failures. VF: Virologic Failure; PR: Protease; RT: Reverse Transcriptase. UDS: Ultra Deep
Sequencing; DRMs: Drug Resistance Mutations. 36 patients without PI resistance mutations at VF by standard genotype were evaluated by UDS. 36
patients with VF had PR evaluated by UDS. 24/36 samples had HIV VL.10,000 c/ml. 9/24 had PI DRMs at low levels. 12/36 samples had HIV
VL,10,000 c/ml. 4/12 had PI DRMs at low levels. Only 3/36 patients with VF had PI mutations with HIVdb weight .12 for ATV or LPV. 24/36 patients
with HIV VL.10,000 c/ml had RT evaluated by UDS. 18/24 samples had NRTI DRMs.
doi:10.1371/journal.pone.0030118.g001
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failures. Further, we were unable to perform ultra deep sequencing
on 21 virologic failure specimens that had an HIV viral load
#1,000 c/mL. Full length reverse transcriptase ultra deep
sequencing for samples with HIV VL.10,000 c/mL was limited
to 24 samples. Given stochastic effects of RNA sampling for the
samples with HIV VL,10,000 c/mL, the reported variants may
or may not represent the proportion of variants in plasma. Thus,
we are unable to confidently analyze all specimens to low levels
which may have lead to an undetected selection bias.
Conclusion
In conclusion, among patients on an initial PI/r based regimen
experiencing virologic failure without PI mutations by standard
genotyping, low-level variants possessing major PI mutations by
ultra deep sequencing were infrequently identified and if PI
mutations were present they were found in isolation and did not
result in phenotypic PI resistance. Only 3 patients (8.3%) had a PI
mutation with a Stanford algorithm weight .12 for ATV or LPV,
however they were at very low levels (,1%) with low mutational
loads. NRTI mutations were detected in a high proportion of
patients with virologic failure and with greater frequency than PI
mutations. These data suggest that PIs may remain effective in
patients experiencing virologic failure on a PI/r-based regimen,
and may be re-used in subsequent ARV regimens with new
optimized background therapy when PI resistance are not detected
by standard or ultra deep sequencing. As the HIV population
grows older, clinicians will need to conserve agents and use potent
and relatively safer ARVs for as long as possible.
These data were presented in part at the 2010 International
HIV & Hepatitis Virus Drug Resistance Conference. Dubrovnik,
Croatia, Abstract #102.
Supporting Information
Table S1 UDS data for RT and PR and phenotype for
24/36 VF subjects. Ultra deep sequencing, mutational load,
and phenotypic susceptibility results for 24 samples from subjects
experiencing virologic failure on TDF+FTC+PI/r. # UDS for
two virologic failure (VF) timepoints – both VF specimens had a
M184V mutation. NRTI DRMs: M184V and K65R are bolded
in black. PI DRMs with a Stanford HIVdb weight .5 are bolded
in black with an asterix *. Please note that if a sample had different
HIV variants with the same mutation they are listed separately e.g.
Subject #2 had different HIV variants with a M184V at 3.92%
and M184V at 94.94%.
(DOCX)
Table S2 UDS data for PR only and phenotype for 12/36
VF subjects. Ultra deep sequencing and mutational load for PIs
only, and phenotypic susceptibility results for 12 samples from
subjects experiencing virologic failure on TDF+FTC+PI/r. PI
DRMs with a Stanford HIVdb weight .5 are bolded.
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